Patients with ADG consumption experienced more ALT elevation than in those without ADG, and patients with NAFLD who had gained weight were independently associated with an increased ALT > 3 U/L compared to baseline. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.